CT, MRI and PET/CT features of abdominal manifestations of cutaneous melanoma: a review of current concepts in the era of tumor-specific therapies.
Computed, X-ray
Immune-induced adverse events
Magnetic resonance imaging
Melanoma, cutaneous malignant
Positron emission tomography-computed tomography
Journal
Abdominal radiology (New York)
ISSN: 2366-0058
Titre abrégé: Abdom Radiol (NY)
Pays: United States
ID NLM: 101674571
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
11
08
2020
accepted:
20
10
2020
revised:
15
10
2020
pubmed:
3
11
2020
medline:
22
6
2021
entrez:
2
11
2020
Statut:
ppublish
Résumé
Abdominal manifestations in patients with cutaneous melanoma include involvement due to metastatic spread and immune checkpoint inhibitor induced adverse events. The purpose of this review is to provide a critical overview of abdominal manifestations in patients with cutaneous melanoma and highlight the current imaging challenges in the era of tumor-specific therapies. Immune checkpoint inhibitors represent a treatment with demonstrated efficacy in the treatment of advanced cutaneous melanoma but are associated with several abdominal adverse events that must be recognized. CT has a role in the identification of colitis, enteritis and pancreatitis, whereas MRI has an important role in the diagnosis of autoimmune pancreatitis. Current evidence demonstrates that MRI should be the preferred imaging technique for the detection and characterization of hepatic and splenic metastases from cutaneous melanoma. The role of
Identifiants
pubmed: 33135115
doi: 10.1007/s00261-020-02837-4
pii: 10.1007/s00261-020-02837-4
doi:
Substances chimiques
Radiopharmaceuticals
0
Fluorodeoxyglucose F18
0Z5B2CJX4D
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
2219-2235Références
Carr S, Smith C, Wernberg J. Epidemiology and Risk Factors of Melanoma. Surg Clin North Am 2020;100(1):1–12.
pubmed: 31753105
Rastrelli M, Tropea S, Rossi CR, Alaibac M. Melanoma: epidemiology, risk factors, pathogenesis, diagnosis and classification. In Vivo 2014;28(6):1005–1011.
Pasquali S, Haydu LE, Scolyer RA, Winstanley JB, Spillane AJ, Quinn MJ, et al. The importance of adequate primary tumor excision margins and sentinel node biopsy in achieving optimal locoregional control for patients with thick primary melanomas. Ann Surg 2013;258(1):152–157.
pubmed: 23426339
Duncan LM. The classification of cutaneous melanoma. Hematol Oncol Clin North Am 2009;23(3):501–513.
pubmed: 19464599
Benaissa A, Fornès P, Ladam-Marcus V, Grange F, Amzallag-Bellenger E, Hoeffel C. Multimodality imaging of melanoma metastases to the abdomen and pelvis. Clin Imaging 2011;35(6):452–458.
pubmed: 22040790
Chang ST, Desser TS, Gayer G, Menias CO. Metastatic melanoma in the chest and abdomen: the great radiologic imitator. Semin Ultrasound CT MR 2014;35(3):272–289.
pubmed: 24929267
Patnana M, Bronstein Y, Szklaruk J, Bedi DG, Hwu WJ, Gershenwald JE, et al. Multimethod imaging, staging, and spectrum of manifestations of metastatic melanoma. Clin Radiol 2011;66(3):224–236.
pubmed: 21295201
Dancey AL, Mahon BS, Rayatt SS. A review of diagnostic imaging in melanoma. J Plast Reconstr Aesthet Surg 2008;61(11):1275–1283.
pubmed: 18694659
King DM. Imaging of metastatic melanoma. Cancer Imaging 2006;6:204-208.
pubmed: 17208677
Mocellin S, Nitti D. CTLA‐4 blockade and the renaissance of cancer immunotherapy. Biochim Biophys Acta 2013;1836(2):187–196.
pubmed: 23748107
Polsky D, Cordon-Cardo C. Oncogenes in melanoma. Oncogene 2003;22:3087–3091.
pubmed: 12789285
Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011;29(10):1239–1246.
pubmed: 21343559
Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell 2015;161(7):1681–96
Pasquali S, Chiarion-Sileni V, Rossi CR, Mocellin S. Immune checkpoint inhibitors and targeted therapies for metastatic melanoma: a network meta-analysis. Cancer Treat Rev 2017;54:34–42.
pubmed: 28189914
Bello DM, Panageas KS, Hollmann T, Shoushtari AN, Momtaz P, Chapman PB, et al. Survival outcomes after metastasectomy in melanoma patients categorized by response to checkpoint blockade. Ann Surg Oncol 2019;27(4):1180–1188.
pubmed: 31848819
pmcid: 7112166
Larkin J, Vanna Chiarion-Sileni V, Gonzalez R, Grob JJ, Lance Cowey C, Lao CD et al. Combined nivolumab and ipilimumab or monotherapy in previously untreated melanoma. N Engl J Med 2015;373(1):23–34.
pubmed: 26027431
pmcid: 26027431
Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al; KEYNOTE-006 investigators. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015;372(26):2521–2532.
pubmed: 25891173
Sanlorenzo M, Vujic I, Posch C, Dajee A, Yen A, Kim S, et al. Melanoma immunotherapy. Cancer Biol Ther 2014;15(6):665e74.
pubmed: 24651672
pmcid: 4049781
Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 2018;378(2):158e68.
pubmed: 29320654
Laurent V, Trausch G, Bruot O, Olivier P, Felblinger J, Régent D. Comparative study of two whole body imaging techniques in the case of melanoma metastases: advantages of multi-contrast MRI examination including a diffusion-weighted sequence in comparison with PETCT. Eur J Radiol 2009;75:376–383.
pubmed: 19497694
Pfannenberg C, Aschoff P, Schanz S, Eschmann SM, Plathow C, Eigentler TK, et al. Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant melanoma. Eur J Cancer 2007;43(3):557–564.
pubmed: 17224266
Muller-Horvat C, Radny P, Eigentler TK, Schäfer J, Pfannenberg C, Horger M, et al. Prospective comparison of the impact on treatment decisions of whole body MRI and CT in patients with metastatic malignant melanoma. Eur J Cancer 2006;42(3):342–343.
pubmed: 16364631
Uhrig M, Simons D, Bonekamp D, Schlemmer HP. Improved detection of melanoma metastases by iodine maps from dual energy CT. Eur J Radiol 2017;90:27–33.
pubmed: 28583644
Namasivayam S, Martin DR, Saini S. Imaging of liver metastases: MRI. Cancer Imaging 2007;7(1):2–9.
pubmed: 17293303
pmcid: 1804118
Keraliya AR, Krajewski KM, Braschi-Amirfarzan M, Tirumani SH, Shinagare AB, Jagannathan JP, et al. Extracutaneous melanomas: a primer for the radiologist. Insights Imaging 2015;6(6):707–717.
pubmed: 26334521
pmcid: 4656230
Wagner M, Mariani P, Bidard FC, Rodrigues MJ, Farkhondeh F, Cassoux N, et al. Diffusion-weighted MRI for uveal melanoma liver metastasis detection. Eur Radiol 2015;25(8):2263–2273.
pubmed: 25712144
Schmidt GP, Baur-Melnyk A, Herzog P, Schmid R, Tiling R, Schmidt M, et al. High-resolution whole-body magnetic resonance image tumor staging with the use of parallel imaging versus dual-modality positron emission tomography-computed tomography: experience on a 32-channel system. Invest Radiol 2005;40(12):743–753.
pubmed: 16304476
Sofue K, Tateishi U, Tsurusaki M, Arai Y, Yamazaki N, Sugimura K. MR imaging of hepatic metastasis in patients with malignant melanoma: evaluation of suspected lesions screened at contrast-enhanced CT. Eur J Radiol 2012;81(4):714–748.
pubmed: 21353412
Ghanem N, Altehoefer C, Högerle S, Nitzsche E, Lohrmann C, Schäfer O, et al. Detectability of liver metastases in malignant melanoma: prospective comparison of magnetic resonance imaging and positron emission tomography. Eur J Radiol 2005;54(2):264–270.
pubmed: 15837408
Schröer-Günther MA, Wolff RF, Westwood ME, Scheibler FJ, Schürmann C, Baumert BG, et al. F-18-fluoro-2-deoxyglucose positron emission tomography (PET) and PET/computed tomography imaging in primary staging of patients with malignant melanoma: a systematic review. Syst Rev 2012;1:62.
pubmed: 23237499
pmcid: 3536719
Bastiaannet E, Wobbes T, Hoekstra OS, van der Jagt EJ, Brouwers AH, Koelemij R, et al. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment. J Clin Oncol 2009;27(28):4774–4780.
pubmed: 19720925
Durot C, Mulé S, Soyer P, Marchal A, Grange F, Hoeffel C. Metastatic melanoma: pretreatment contrast-enhanced CT texture parameters as predictive biomarkers of survival in patients treated with pembrolizumab. Eur Radiol 2019;29(6):3183–3191.
pubmed: 30645669
Schraag A, Klumpp B, Afat S, Gatidis S, Nikolaou K, Eigentler TK, et al. Baseline clinical and imaging predictors of treatment response and overall survival of patients with metastatic melanoma undergoing immunotherapy. Eur J Radiol 2019;121:108688.
pubmed: 31704599
Backman H. Metastasis of malignant melanoma in the gastrointestinal tract. Geriatrics 1999;24(8):112–120.
Das Gupta T, Brasfield RD. Metastatic melanoma to the gastrointestinal tract. Arch Surg 1964;88:969–973.
Antonini F, Acito L, Sisti S, Angelelli L, Macarri G. Metastatic melanoma of the gallbladder diagnosed by EUS-guided FNA. Gastrointest Endosc 2016;84(6):1072–1073.
pubmed: 26902847
Dong XD, DeMatos P, Prieto VG, Seigler HF. Melanoma of the gallbladder: a review of cases seen at Duke University Medical Center. Cancer 1999;85(1):32–39.
pubmed: 9921971
Medina V, Darnell A, Bejarano N, Falcó J, Musulen E, Martin J. Primary biliary tract malignant melanoma: US, CT, and MR findings. Abdom Imaging 2003;28(6):842–846.
pubmed: 14753603
Guida M, Cramarossa A, Gentile A, Benvestito S, De Fazio M, Sanbiasi D, et al. Metastatic malignant melanoma of the gallbladder: a case report and review of the literature. Melanoma Res 2002;12(6):619–625.
pubmed: 12459652
Rehani B, Strohmeyer P, Jacobs M, Mantil J. Gallbladder metastasis from malignant melanoma: diagnosis with FDG PET/CT. Clin Nucl Med 2006;31(12):812–823.
pubmed: 17117082
O’Connell JB, Whittemore DM, Russell JC, Ellis WA, Becker DR. Malignant melanoma metastatic to the cystic duct and common bile ducts. Cancer 1984;53(1):184–186.
pubmed: 6360328
Wagner MS, Shoup M, Pickleman J, Yong S. Primary malignant melanoma of the common bile duct: a case report and review of the literature. Arch Pathol Lab Med 2000;124(3):419–422.
pubmed: 10705398
Garas G, Bramston B, Edmunds SE. Malignant melanoma metastatic to the common bile duct. J Gastroenterol Hepatol 2000;15(11):1348–1351.
pubmed: 11129234
Reintgen DS, Thompson W, Garbutt J, Seigler HF Radiologic, endoscopic, and surgical considerations of melanoma metastatic to the gastrointestinal tract. Surgery 1984;95(6):635–639.
pubmed: 6203181
Albert JG, Fechner M, Fiedler E, Voderholzer W, Lochs H, Trefzer U, et al. Algorithm for detection of small-bowel metastasis in malignant melanoma of the skin. Endoscopy 2011;43(6):490–498.
pubmed: 21618149
Tsilimparis N, Menenakos C, Rogalla P, Braumann C, Hartmann J. Malignant melanoma metastasis as a cause of small-bowel perforation. Onkologie 2009;32(6):356–358.
pubmed: 19521125
Butte JM, Meneses M, Waugh E, Parada H, De La Fuente H. Ileal intussusception secondary to small bowel metastases from melanoma. Am J Surg 2009;198(1):e1–e2.
pubmed: 19268910
Bender GN, Maglinte DD, McLarney JH, Rex D, Kelvin FM. Malignant melanoma: patterns of metastasis to the small bowel, reliability of imaging studies, and clinical relevance. Am J Gastroenterol 2001;96(8):2392–2400.
pubmed: 11513180
Panagiotou I, Brountzos EN, Bafaloukos D, Stoupis C, Brestas P, Kelekis DA. Malignant melanoma metastatic to the gastrointestinal tract. Melanoma Res 2002;12(2):169–173.
pubmed: 11930114
Crippa S, Bovo G, Romano F, Mussi C, Uggeri F. Melanoma metastatic to the gallbladder and small bowel: report of a case and review of the literature. Melanoma Res 2004;14(5):427–430.
pubmed: 15457102
Mucci T, Long W, Witkiewicz A, Mastrangelo MJ, Rosato EL, Berger AC. Metastatic melanoma causing jejunal intussusception. J Gastrointest Surg 2007;11(12):1755–1757.
pubmed: 17619936
Othman AE, Eigentler TK, Bier G, Pfannenberg C, Bösmüller H, Thiel C, et al. Imaging of gastrointestinal melanoma metastases: Correlation with surgery and histopathology of resected specimen. Eur Radiol 2017;27(6):2538–2545.
pubmed: 27752834
Lens M, Bataille V, Krivokapic Z. Melanoma of the small intestine. Lancet Oncol 2009;10(5):516–521.
pubmed: 19410196
Prakoso E, Selby WS. Capsule endoscopy in patients with malignant melanoma. Am J Gastroenterol 2007;102(6):1204–1208.
pubmed: 17324125
Prakoso E, Fulham M, Thompson JF, Selby WS. Capsule endoscopy versus positron emission tomography for detection of small-bowel metastatic melanoma: a pilot study. Gastrointest Endosc 2011;73(4):750–756.
pubmed: 21288518
Khalife S, Soyer P, Alatawi A, Vahedi K, Hamzi L, Dray X, et al. Obscure gastrointestinal bleeding: preliminary comparison of 64-section CT enteroclysis with video capsule endoscopy. Eur Radiol 2011;21(1):79-86.
pubmed: 20652705
Soyer P, Aout M, Hoeffel C, Vicaut E, Placé V, Boudiaf M. Helical CT-enteroclysis in the detection of small-bowel tumours: a meta-analysis. Eur Radiol 2013;23(2):388–399.
pubmed: 22865269
Soyer P, Boudiaf M, Fishman EK, Hoeffel C, Dray X, Manfredi R, et al. Imaging of malignant neoplasms of the mesenteric small bowel: new trends and perspectives. Crit Rev Oncol Hematol 2011;80(1):10–30.
pubmed: 21035353
Liang KV, Sanderson SO, Nowakowski GS, Arora AS. Metastatic malignant melanoma of the gastrointestinal tract. Mayo Clin Proc 2006;81(4):511–516.
pubmed: 16610571
Patel JK, Didolkar MS, Pickren JW, Moore RH. Metastatic pattern of malignant melanoma: a study of 216 autopsy cases. Am J Surg 1978;135(6):807–810.
pubmed: 665907
Michalinos A, Felekouras E, Athanasiou A, Tsaparas P, Mantas D, Kouraklis G. Melanoma metastases to gastrointestinal tract. Am Surg 2015;81(5):E212–214.
pubmed: 25975313
Wang J, Ao WQ, Liu C, Zhang WM, Xu FY. Primary gastric melanoma: a case report with imaging findings and 5-year follow-up. World J Gastroenterol 2019; 25(44): 6571–6578.
pubmed: 31802836
pmcid: 6886020
Tessier DJ, McConnell EJ, Young-Fadok T, Wolff BG. Melanoma metastatic to the colon: case series and review of the literature with outcome analysis. Dis Colon Rectum 2003;46(4):441–447.
pubmed: 12682534
Eloubeidi MA, Gaede JT, Davis WZ. Isolated metastatic melanoma to the colon mimicking colon cancer. Gastrointest Endosc 2000;52(6):751–752.
pubmed: 11115908
Park JS, Ng KS, Saw RPM, Thompson JF, Young CJ. Metastatic melanoma to the colon, rectum, and anus: a 50-year experience. Ann Surg Oncol 2018;25(8):2178–2183.
pubmed: 29691736
Watson RGK, McMullin JP. Intussusception of the colon secondary to gastrointestinal metastatic melanoma. J R Coll Surg Edinb 1980;25(3):200–201.
pubmed: 7218190
Grignon DJ, Ro JY, Varona OB, et al. Malignant melanoma with metastasis to a colonic polyp. Am J Gastroenterol 1988; 83(11):1298–1300.
pubmed: 3055948
McClenathan JH. Metastatic melanoma involving the colon. Dis Col Rectum 1989;32(31):70–72.
Galloro G, Inzirillo A, Magno L, Diamantis G, Inzirillo M, Pastore A, et al. Multiple nodular lesions by colonic metastatic malignant melanoma. Dig Liver Dis 2009;41(2):169.
pubmed: 18619931
Kinner S, Lauenstein TC. MR colonography. Radiol Clin North Am 2007;45(2):377–387.
pubmed: 17502224
Untch BR, Allen PJ. Pancreatic metastasectomy: the Memorial Sloan-Kettering experience and a review of the literature. J Surg Oncol 2014;109(1):28–30.
pubmed: 24122337
Barral M, Faraoun SA, Fishman EK, Dohan A, Pozzessere C, Berthelin MA, et al. Imaging features of rare pancreatic tumors. Diagn Interv Imaging 2016;97(12):1259–1273.
pubmed: 27825642
Sperti C, Polizzi ML, beltrame V, Moro M, Pedrazzoli S. Pancreatic resection for metastatic melanoma: case report and review of the literature. J Gastrointest Cancer 2011;42(4):302–306.
pubmed: 20524082
Brodish RJ, McFadden DW. The pancreas as the solitary site of metastasis from melanoma. Pancreas 1993;8(2):276–278.
pubmed: 8460104
Pang JC, Roh MH. Metastases to the pancreas encountered on endoscopic ultrasound-guided fine-needle aspiration. Arch Pathol Lab Med 2015;139(10):1248–1252.
pubmed: 26414469
DeWitt JM, Chappo J, Sherman S. Endoscopic ultrasound-guided fine-needle aspiration of melanoma metastatic to the pancreas: report of two cases and review. Endoscopy 2003;35(3):219–222.
pubmed: 12584640
Wood TF, DiFronzo LA, Rose DM, Haigh PI, Stern SL, Wanek L, et al. Does complete resection of melanoma metastatic to solid intra-abdominal organs improve survival? Ann Surg Oncol 2001;8(8):658–662.
pubmed: 11569781
Scatarige JC, Horton KM, Sheth S, Fishman EK. Pancreatic parenchymal metastases: observations on helical CT. AJR Am J Roentgenol 2001;176(3):695–699.
pubmed: 11222207
Jana T, Caraway NP, Irisawa A, Manoop S, Bhutani MS. Multiple pancreatic metastases from malignant melanoma: Conclusive diagnosis with endoscopic ultrasound-guided fine needle aspiration. Endosc Ultrasound 2015;4(2):145–148.
pubmed: 26020050
pmcid: 4445173
Merkle EM, Boaz T, Kolokythas O, Haaga JR, Lewin JS, Brambs HJ. Metastases to the pancreas. Br J Radiol 1998;71(851):1208–1214.
pubmed: 10434919
Klein KA, Stephens DH, Welch TJ. CT characteristics of metastatic disease of the pancreas. Radiographics 1998;18(2):369–378
pubmed: 9536484
Nakamura Y, Yamada R, Kaneko M, Naota H, Fujimura Y, Tabata M, et al. Isolated pancreatic metastasis from malignant melanoma: a case report and literature review. Clin J Gastroenterol 2019;12(6):626–636.
pubmed: 31134450
pmcid: 6885028
Nikfarjam M, Evans P, Christophi C. Pancreatic resection for metastatic melanoma. HPB 2003;5(3):174–179.
pubmed: 18332980
pmcid: 2020574
Shirkhoda A, Albin J. Malignant melanoma: correlating abdominal and pelvic CT with clinical staging. Radiology 1987;165(1):75–78.
pubmed: 3628793
Das Gupta T, Brasfield R. Metastatic melanoma: a clinic pathological study. Cancer 1964;17:1323–1339.
Badet N, Sailley N, Briquez C, Paquette B, Vuitton L, Delabrousse É. Mesenteric panniculitis: still an ambiguous condition. Diagn Interv Imaging 2015;96(3):251–257.
pubmed: 25701479
Protin-Catteau L, Thiéfin G, Barbe C, Jolly D, Soyer P, Hoeffel C. Mesenteric panniculitis: review of consecutive abdominal MDCT examinations with a matched-pair analysis. Acta Radiol 2016;57(12):1438–1444.
pubmed: 26868171
Soyer P, Hoeffel C, Zins M. Mesenteric panniculitis: more research is needed. Diagn Interv Imaging 2015;96(3):225-256.
pubmed: 25744937
Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS. Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res 2016;22(4):886–894.
pubmed: 26446948
Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711–723.
pubmed: 20525992
pmcid: 3549297
Tirumani SH, Ramaiya NH, Keraliya A, Bailey ND, Ott PA, Hodi FS, et al. Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res 2015;3(10):1185–1192.
pubmed: 26100356
pmcid: 4596761
Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 2019;16:563–580.
pubmed: 31092901
Bronstein Y, Ng CS, Hwu P, Hwu WJ. Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti–CTLA-4 antibody therapy. AJR Am J Roentgenol 2011;197(6):W992–W1000.
pubmed: 22109345
Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018;29(Supplement 4):iv264–iv266.
Thornton E, Howard SA, Jagannathan J, Krajewski KM, Shinagare AB, O’Regan K, et al. Imaging features of bowel toxicities in the setting of molecular targeted therapies in cancer patients. Br J Radiol 2012;85(1018):1420–1426.
pubmed: 22674709
pmcid: 3474016
Garcia-Neuer M, Marmarelis ME, Jangi SR, Luke JJ, Ibrahim N, Davis M, et al. Diagnostic comparison of CT scans and colonoscopy for immune-related colitis in ipilimumab-treated advanced melanoma patients. Cancer Immunol Res 2017;5(4):286–291.
pubmed: 28373217
Alessandrino F, Sahu S, Nishino M, Adeni AE, Tirumani SH, Shinagare AB, et al. Frequency and imaging features of abdominal immune-related adverse events in metastatic lung cancer patients treated with PD-1 inhibitor. Abdom Radiol 2019;44:1917–1927.
Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol 2018;4(2):173–182.
Graziani R, Mautone S, Ambrosetti MC, Manfredi R, Re TJ, Calculli L, et al. Autoimmune pancreatitis: multidetector-row computed tomography (MDCT) and magnetic resonance (MR) findings in the Italian experience. Radiol Med 2014;119(8):558–571.
pubmed: 24638911
Dehghani L, Mikail N, Kramkimel N, Soyer P, Lebtahi R, Mallone R, et al. Autoimmune pancreatitis after nivolumab anti-programmed death receptor-1 treatment. Eur J Cancer 2018;104:243–246.
pubmed: 30454710
Fan RY, Sheng JQ. Immunoglobulin G4-related autoimmune pancreatitis and sialadenitis: a case report. World J Gastroenterol 2015;21(31):9448-9452.
pubmed: 26309373
pmcid: 4541399
Tanaka T, Sakai A, Kobayashi T, Masuda A, Shiomi H, Kodama Y. Nivolumab-related pancreatitis with autoimmune pancreatitis-like imaging features. J Gastroenterol Hepatol 2019;34(8):1274.
pubmed: 30828866
Park S, Chu LC, Hruban RH, Vogelstein B, Kinzler KW, Yuille AL, et al. Differentiating autoimmune pancreatitis from pancreatic ductal adenocarcinoma with CT radiomics features. Diagn Interv Imaging 2020;101(9):555–564.
pubmed: 32278586
Marchand L, Thivolet A, Saintigny P, Fabien N, Vouillarmet J, Thivolet C. Antiprogrammed death 1 (PD-1) antibodies and the pancreas: a diabetic storm ahead? Diabetes Care 2018;41(3):638e9.
Rawson RV, Robbins E, Kapoor R, Scolyer RA, Long GV. Recurrent bowel obstruction: unusual presentation of pembrolizumab-induced pancreatitis in annular pancreas. Eur J Cancer 2017;82:167–170.
pubmed: 28689094
Raad RA, Pavlick A, Kannan R, Friedman KP. Ipilimumab-induced hepatitis on 18FFDG PET/CT in a patient with malignant melanoma. Clin Nucl Med 2015;40(3):258e9
pubmed: 25290291
Wartski M, Sauvanet A. 18F-FDG PET/CT in pancreatic adenocarcinoma: a role at initial imaging staging? Diagn Interv Imaging 2019;100(12):735–741.
pubmed: 31402332
Alabed YZ, Aghayev A, Sakellis C, Van den Abbeele AD. Pancreatitis secondary to anti-programmed death receptor 1 immunotherapy diagnosed by FDG PET/CT. Clin Nucl Med 2015;40(11):e528e9.
Eshet Y, Baruch EN, Shapira-Frommer R, Steinberg-Silman Y, Kuznetsov T, Ben-Betzalel G, et al. Clinical significance of pancreatic atrophy induced by immune-checkpoint inhibitors: a case-control study. Cancer Immunol Res 2018;6(12):1453–1458.
pubmed: 30275274
Wang GX, Kurra V, Gainor JF, Sullivan RJ, Flaherty KT, Lee SI, et al. Immune checkpoint inhibitor cancer therapy: spectrum of imaging findings. Radiographics 2017;37(7):2132–2144.
pubmed: 29131763
Huffman BM, Kottschade LA, Kamath PS, Markovic SN. Hepatotoxicity after immune checkpoint inhibitor therapy in melanoma: natural progression and management. Am J Clin Oncol 2018;41(8):760–765.
pubmed: 28749795
Kim KW, Ramaiya NH, Krajewski KM, Jagannathan JP, Tirumani SH, Srivastava A, et al. Ipilimumab associated hepatitis: imaging and clinicopathologic findings. Invest New Drugs 2013;31(4):1071–1077.
pubmed: 23408334
Charvet E, Lheure C, Isnard C, Franck N, Kramkimel N, Vallet-Pichard A, et al. Hepatic sinusoidal obstruction syndrome induced by nivolumab in advanced melanoma: a case report. Ann Oncol 2020; https://doi.org/10.1016/j.annonc.2020.02.004 .
doi: 10.1016/j.annonc.2020.02.004
pubmed: 32165097
Wang PF, Chen Y, Song SY, Wang TJ, Ji WJ, Li SW et al. Immune-related adverse events associated with anti-PD-1/PD-L1 treatment for malignancies: a meta-analysis. Front Pharmacol 2017;8:730
pubmed: 29093678
pmcid: 5651530
Wolchok JD, Hoos A, O’Day S, Weber JS, Hamid O, Lebbé C, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 2009;15(23):7412–7420.
pubmed: 19934295
pmcid: 19934295
Solinas C, Porcu M, Hlavata Z, De Silva P, Puzzoni M, Willard-Gallo K, et al. Critical features and challenges associated with imaging in patients undergoing cancer immunotherapy. Crit Rev Oncol Hematol 2017;120:13–21.
pubmed: 29198327
Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. iRECIST: guidelines for response criteria for use in trials testing immunothera-peutics. Lancet Oncol 2017;18(3):e143–e152.
pubmed: 28271869
pmcid: 5648544
Bertrand A, Kostine M, Barnetche T, Truchetet ME, Schaeverbeke T. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med 2015;13:211.
pubmed: 26337719
pmcid: 26337719
Beregi JP, Greffier J. Low and ultra-low dose radiation in CT: opportunities and limitations. Diagn Interv Imaging 2019;100(2):63-64
pubmed: 30733022